Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease
December 20, 2023 08:00 ET
|
Longeveron
New clinical data showed that Lomecel-B™ improved cognitive function in multiple measures in a dose-response fashion Caregiver ratings documented improved quality of life in Lomecel-B™ treated...
Nokia launches gigabit Multi-Dwelling Unit (MDU) solution for cable operators
December 05, 2023 02:30 ET
|
Nokia Oyj
Press Release Nokia launches gigabit Multi-Dwelling Unit (MDU) solution for cable operators Nokia introduces industry’s first integrated, Fiber-to-the-Home (FTTH) and Multimedia over Coax...
Studies: Promising Cognitive and Imaging Results in Alzheimer’s and pre-dementia Patients
November 21, 2023 08:00 ET
|
Posit Science
SAN FRANCISCO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- A pair of articles in the Journal of Alzheimer’s Disease (JAD) from researchers, who conducted a pilot study for the treatment of pre-dementia and...
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
November 16, 2023 16:05 ET
|
Vigil Neuroscience, Inc.
- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream pharmacological activity at 20 mg/kg consistent...
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose
October 23, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed...
Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress
September 07, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress Both VIVIAD and VIVA-MIND studies on track; final data from VIVIAD expected in Q1/2024, and a...
Embrace Esports Exuberance: Mocapart Launches 7 Striking Collections for the 15th ESports World Championship
August 28, 2023 12:00 ET
|
Mocapart
Santa Venera, Malta, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Mocapart, the avant-garde digital art gallery of motion, and the International ESports Federation have announced the launch of seven...
Carbon Composites Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)
August 18, 2023 11:15 ET
|
ReportLinker
New York, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Carbon Composites Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)" -...
Introducing Mocapart: The First NFT Art Gallery of Motion
July 26, 2023 12:00 ET
|
Mocapart
Santa Venera, Malta, July 26, 2023 (GLOBE NEWSWIRE) -- Mocapart, a groundbreaking marketplace, is revolutionizing the world of digital art by unveiling the first-ever NFT Art Gallery of Motion. ...
Introducing Mocapart: The First NFT Art Gallery of Motion
July 25, 2023 12:00 ET
|
Mocapart
Santa Venera, Malta, July 25, 2023 (GLOBE NEWSWIRE) -- Mocapart, a groundbreaking marketplace, is revolutionizing the world of digital art by unveiling the first-ever NFT Art Gallery of Motion. This...